Project Grant R01DE035326
Award Date
7/1/25
Completion Date
3/31/30
Dollars Obligated
$704K
Federal Agency
National Institute of Dental and Craniofacial Research
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $249,000 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to the University of Missouri System to develop a novel organopet assay for precision therapy of head and neck cancer. The key products and services to be delivered under this 3-year grant include: Establishing a high-throughput automated platform to generate patient-derived tumor organoids (tumoroids) that capture tumor...
This federal Project Grant award, titled "Engineering Oral Tumor Microcirculation: Blood and Lymphatic Capillary Network-Enabled Human Oral Tumor Microenvironment Chips for Preclinical Research", is funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The $421,625 award, effective from July 1, 2025 to June 30, 2027, will support the development of advanced tumor microenvironment chips...
This $245,504 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to develop new transgenic mouse models and conduct pre-clinical evaluation of a small molecule inhibitor targeting the replication protein A (RPA) complex. The research focuses on enhancing treatment responses for oral squamous cell carcinoma (OSCC) by exploiting the stress-specific functions of RPA. Key...
This $390,000 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to identify tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). The key products and services to be delivered include: Developing a high-throughput, single-cell co-culture system to isolate individual tumor-killing T cells and identify their T cell receptors (TCRs). Performing...
This federal Project Grant award of $429,000.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program. The grant supports research to determine the functional roles and mechanisms of the human microbiome and metabolome in the pathogenesis of oral squamous cell carcinoma (OSCC), a prevalent and lethal form of head and neck cancer. The research aims to 1) define OSCC-associated metagenomic and...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $808,264 Project Grant under the Oral Diseases and Disorders Research (CFDA 93.121) federal grant program to The Medical University of South Carolina. The grant aims to elucidate the mechanisms underlying filopodia-mediated intracellular uptake of a cell-penetrating peptide (RD3AD) complex carrying small interfering RNAs (siRNAs), and to determine its ability to target and deliver siRNAs to migrating/invading oral...
This $612,048 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) supports research to investigate the role of the lysyl oxidase propeptide (LOX-PP) in regulating macrophage phenotypes and their impact on oral squamous cell carcinoma (OSCC) tumor suppression. The research aims to characterize the differential effects of wildtype versus variant LOX-PP on macrophage activation,...
This $799,270 federal project grant awarded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) will support the development of a novel class of anticancer drugs called 1,3-thioureas for the treatment of oral squamous cell carcinoma (OSCC). The grant recipient, Keraceuticals, Inc., will focus on formulating the lead compound CIDD99 for oral and/or intravenous administration, evaluating its efficacy in mouse...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $164,322 to the Regents of the University of Michigan to investigate the evolution of pro-tumoral myeloid cells during the initiation of oral cancer. The researchers will utilize a preclinical mouse model to study the transition from oral epithelial dysplasia to head and neck squamous cell carcinoma, with a focus on...